Alnylam Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Alnylam Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Alnylam Pharmaceuticals Inc Strategy Report
- Understand Alnylam Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Alnylam Pharmaceuticals Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| EP4058577A1 | Application | VERFAHREN UND ZUSAMMENSETZUNGEN ZUM BEHANDELN EINER ANGIOTENSINOGEN- (AGT-) ASSOZIIERTEN STÖRUNG | C12N15/113; C12N2310/14; C12N2310/315; C12N2310/32; C12N2310/351; C12N2320/31; C12N2320/35; C12N2320/52 | September 21, 2022 |
| WO2022192519A1 | Application | GLYCOGEN SYNTHASE KINASE 3 ALPHA (GSK3A) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | C12N15/1137; C12N2310/14; C12N2310/315; C12N2310/317; C12N2310/32; C12N2310/3515; C12Y207/11001; C12Y207/11026 | September 15, 2022 |
| AU2020204161B2 | Grant | Complement component C5 iRNA compositions and methods of use thereof | A61K31/7088; A61K31/713; A61K39/3955; A61K47/14; A61K48/00; A61P1/04; A61P11/06; A61P13/02; A61P13/12; A61P15/06; A61P17/02; A61P17/06; A61P19/02; A61P21/00; A61P21/04; A61P25/00; A61P25/28; A61P27/02; A61P29/00; A61P3/10; A61P31/04; A61P37/00; A61P37/06; A61P39/02; A61P5/14; A61P7/00; A61P7/02; A61P7/04; A61P7/06; A61P9/00; A61P9/08; A61P9/10; A61P9/12; A61P9/14; C07K16/18; C07K2317/24; C07K2317/76; C12N15/113; C12N2310/14; C12N2310/3125; C12N2310/315; C12N2310/321; C12N2310/351; C12N2310/3527; C12N2320/30 | September 15, 2022 |
| UA126276C2 | Grant | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES | A61K48/00; A61P25/00; A61P25/02; A61P25/28; A61P43/00; A61P5/14; A61P7/00; A61P9/00; C12N15/113; C12N2310/14; C12N2310/315; C12N2310/322; C12N2310/344; C12N2310/351; C12N2310/3515; C12N2310/3533; C12N2320/30 | September 14, 2022 |
| UA126266C2 | Grant | COMPOSITIONS AND METHODS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | A61K31/00; A61K31/713; A61K45/00; A61K45/06; A61K47/549; A61P13/00; A61P13/12; A61P43/00; C12N15/113; C12N15/1137; C12N2310/14; C12N2310/315; C12N2310/32; C12N2310/321; C12N2310/344; C12N2310/346; C12N2310/351; C12N2310/3515; C12Y101/03015 | September 14, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer